Last reviewed · How we verify
NCT03353441
Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor
NA trial testing Microencapsulated Sublingual Glycine (MSG) in Healthy in 90 participants. Completed in 15 June 2018.
15 March 2018
Quick facts
| Lead sponsor | Daacro |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 15 November 2017 |
| Primary completion | 15 March 2018 |
| Estimated completion | 15 June 2018 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Microencapsulated Sublingual Glycine (MSG)
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
- Stress, Psychological — all drugs for Stress, Psychological →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Daacro
Who can join
Adults 18 to 40, male only, with Healthy or Stress, Psychological. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to assess whether intake of Glycine (MSG) leads to an increase of cognitive performance after an acute stressor compared to placebo. One group will receive verum, one group placebo and one group will not receive any intervention. Cognitive testing will be performed in connection with the Trier Social Stress Test (TSST).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03353441
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Daacro trials
Trials by the same sponsor.
- NCT04876261 — Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements · NA · completed
- NCT03494725 — Stress & Anxiety Dampening Effects of a Probiotic Supplement Compared to Placebo in Healthy Subjects · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03353441 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daacro
- Last refreshed: 26 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03353441.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing